These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 10093585)
1. Management of early Parkinson's disease. Hauser RA; Zesiewicz TA Med Clin North Am; 1999 Mar; 83(2):393-414, vi. PubMed ID: 10093585 [TBL] [Abstract][Full Text] [Related]
6. New concepts in the treatment of Parkinson's disease. Ahlskog JE; Wilkinson JM Am Fam Physician; 1990 Feb; 41(2):574-84. PubMed ID: 1967895 [TBL] [Abstract][Full Text] [Related]
7. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs? Clarke CE Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811 [TBL] [Abstract][Full Text] [Related]
8. [Drug therapy of Parkinson's disease]. Myllylä V Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076 [No Abstract] [Full Text] [Related]
10. Early Parkinson's disease: what is the best approach to treatment. Hristova AH; Koller WC Drugs Aging; 2000 Sep; 17(3):165-81. PubMed ID: 11043817 [TBL] [Abstract][Full Text] [Related]
11. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Pålhagen S; Heinonen EH; Hägglund J; Kaugesaar T; Kontants H; Mäki-Ikola O; Palm R; Turunen J Neurology; 1998 Aug; 51(2):520-5. PubMed ID: 9710028 [TBL] [Abstract][Full Text] [Related]
13. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease. Jost WH J Neural Transm (Vienna); 2022 Jun; 129(5-6):723-736. PubMed ID: 35107654 [TBL] [Abstract][Full Text] [Related]
14. Dopamine agonists used as monotherapy in de novo PD patients: comparisons with selegiline. Lieberman A Neurology; 1992 Apr; 42(4 Suppl 4):37-40; discussion 41-8. PubMed ID: 1350073 [TBL] [Abstract][Full Text] [Related]
15. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687 [TBL] [Abstract][Full Text] [Related]
16. Treatment options for early Parkinson's disease. Stacy M; Brownlee HJ Am Fam Physician; 1996 Mar; 53(4):1281-7. PubMed ID: 8629572 [TBL] [Abstract][Full Text] [Related]
17. Treatment of early Parkinson's disease: are complicated strategies justified? Ahlskog JE Mayo Clin Proc; 1996 Jul; 71(7):659-70. PubMed ID: 8656708 [TBL] [Abstract][Full Text] [Related]
18. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. Parkinson Study Group JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889 [TBL] [Abstract][Full Text] [Related]
19. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. Parkinson Study Group JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889 [TBL] [Abstract][Full Text] [Related]
20. Zydis selegiline in the management of Parkinson's disease. Poston KL; Waters C Expert Opin Pharmacother; 2007 Oct; 8(15):2615-24. PubMed ID: 17931095 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]